Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

31.99 +0.34 (+1.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,876,225
Open 32.35
Bid (Size) 32.03 (400)
Ask (Size) 32.18 (2,100)
Prev. Close 31.65
Today's Range 31.79 - 32.94
52wk Range 18.92 - 43.15
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property

Performance

YTD
-9.7%
-9.7%
1 Month
-14.8%
-14.8%
3 Month
-4.7%
-4.7%
6 Month
+2.8%
+2.8%
1 Year
-18.6%
-18.6%

More News

Read More
News headline image
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
Via MarketMinute
Topics Economy
News headline image
Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026
Via MarketMinute
Topics Economy
News headline image
The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms ↗
Via Stocktwits
News headline image
The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026
Via MarketMinute
Topics Economy Intellectual Property
News headline image
2 Beaten-Down Stocks That Could Bounce Back in 2026 ↗
Via The Motley Fool
News headline image
The Motley Fool Rule Breakers Besties of 2025 ↗
Via The Motley Fool
News headline image
The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill
Via PredictStreet
Topics Economy Intellectual Property World Trade
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
Via PredictStreet
Topics Economy Government Intellectual Property
News headline image
The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era
Via PredictStreet
Topics Economy
News headline image
Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market
Via MarketMinute
News headline image
The Great Rotation: Small-Caps Break All-Time Highs as Investors Pivot from Mega-Tech
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The Great Rotation: Why the Russell 2000 is Finally Outpacing the Giants in Late 2025
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics ↗
Via Stocktwits
News headline image
2 Growth Stocks to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
1 Bold Prediction for Viking Therapeutics in 2026 ↗
Via The Motley Fool
News headline image
2 Monster Stocks in the Making to Buy and Hold ↗
Via The Motley Fool
News headline image
My Top 10 Stocks to Buy for 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
What's Up With The Jump In Viking Therapeutics Stock? ↗
Via Benzinga
News headline image
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗
Via The Motley Fool
News headline image
Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗
Via Stocktwits

Frequently Asked Questions

Is Viking Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viking Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viking Therapeutics, Inc. - Common Stock trade on?
Viking Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viking Therapeutics, Inc. - Common Stock?
The ticker symbol for Viking Therapeutics, Inc. - Common Stock is VKTX on the Nasdaq Stock Market
What is the current price of Viking Therapeutics, Inc. - Common Stock?
The current price of Viking Therapeutics, Inc. - Common Stock is 31.99
When was Viking Therapeutics, Inc. - Common Stock last traded?
The last trade of Viking Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET
What is the market capitalization of Viking Therapeutics, Inc. - Common Stock?
The market capitalization of Viking Therapeutics, Inc. - Common Stock is 3.19B
How many shares of Viking Therapeutics, Inc. - Common Stock are outstanding?
Viking Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.